• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
OMER

OMER

Omeros Corporation

NASDAQHealthcareBiotechnologyUS

USD10.16

-0.10 (-0.97%)

Rating:C+

Company Profile

CEO

Gregory A. Demopulos

IPO Date

2009-10-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.21

Prev. Close

$10.26

Day Low

$9.86

Day High

$10.22

52W Low

$2.95

52W High

$17.65

Market Cap

$0.74B

Volume

1.85M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

17.3%

Avg Negative

21.9%

Avg Neutral

60.8%

News Feed

Omeros: PDUFA Delay Presents An Opportunity

Seeking Alpha·7/3/2021·↓ negative

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

Zacks Investment Research·6/10/2021·↑ positive

Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

Business Wire·6/10/2021·↑ positive

Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

Business Wire·6/9/2021·↓ negative

Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

Business Wire·6/9/2021·↑ positive

Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients

Zacks Investment Research·5/31/2021·↑ positive

Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients

Benzinga·5/28/2021·↑ positive

Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab

Business Wire·5/28/2021·↑ positive

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

Newsfile Corp·5/22/2021·↓ negative

Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

Zacks Investment Research·5/21/2021·↓ negative